JP2016520534A - インフルエンザ核タンパク質ワクチン - Google Patents

インフルエンザ核タンパク質ワクチン Download PDF

Info

Publication number
JP2016520534A
JP2016520534A JP2016503642A JP2016503642A JP2016520534A JP 2016520534 A JP2016520534 A JP 2016520534A JP 2016503642 A JP2016503642 A JP 2016503642A JP 2016503642 A JP2016503642 A JP 2016503642A JP 2016520534 A JP2016520534 A JP 2016520534A
Authority
JP
Japan
Prior art keywords
influenza
antigen
fusion protein
seq
imx313
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016503642A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016520534A5 (enExample
Inventor
ジュディス、デル、カンポ、アスカラテイル
フェルガル、ヒル
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imaxio SA
Original Assignee
Imaxio SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imaxio SA filed Critical Imaxio SA
Publication of JP2016520534A publication Critical patent/JP2016520534A/ja
Publication of JP2016520534A5 publication Critical patent/JP2016520534A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2016503642A 2013-03-18 2014-03-18 インフルエンザ核タンパク質ワクチン Pending JP2016520534A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13305320.7 2013-03-18
EP13305320 2013-03-18
PCT/EP2014/055438 WO2014147087A1 (en) 2013-03-18 2014-03-18 Influenza nucleoprotein vaccines

Publications (2)

Publication Number Publication Date
JP2016520534A true JP2016520534A (ja) 2016-07-14
JP2016520534A5 JP2016520534A5 (enExample) 2017-04-13

Family

ID=48044708

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016503642A Pending JP2016520534A (ja) 2013-03-18 2014-03-18 インフルエンザ核タンパク質ワクチン

Country Status (11)

Country Link
US (2) US9243047B2 (enExample)
EP (1) EP2976357B1 (enExample)
JP (1) JP2016520534A (enExample)
KR (1) KR102379951B1 (enExample)
CN (2) CN105143251B (enExample)
AU (1) AU2014234363B2 (enExample)
BR (1) BR112015023738B8 (enExample)
CA (1) CA2901888C (enExample)
MX (1) MX363149B (enExample)
RU (1) RU2662667C2 (enExample)
WO (1) WO2014147087A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2677799C2 (ru) * 2012-12-11 2019-01-21 Озивакс Сас Модифицированные суперспиральные белки с улучшенными свойствами
WO2020210003A2 (en) * 2019-03-21 2020-10-15 Georgia State University Research Foundation, Inc. Virus-like particles and uses thereof
CA3230305A1 (en) 2021-08-24 2023-03-02 Osivax Belgique Immunogenic compositions and their use
CA3242433A1 (en) 2021-12-22 2023-06-29 Osivax Vaccine compositions and their use
CA3253732A1 (en) 2022-03-22 2023-09-28 Osivax mRNA VACCINE COMPOSITIONS AND THEIR USE
CN115779079A (zh) * 2022-10-01 2023-03-14 中国人民解放军军事科学院军事医学研究院 一种可增强与佐剂协同免疫效力的电荷调控型抗原蛋白
CN117659138B (zh) * 2023-12-25 2025-04-08 华中农业大学 一种流感病毒np蛋白突变体及其应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0795888A (ja) * 1993-03-18 1995-04-11 Merck & Co Inc 核酸製剤
JP2007528210A (ja) * 2003-08-12 2007-10-11 アヴィディス エスアー Ｃ４ｂｐコアタンパク質及び単量体抗原を含む生成物及びその使用
JP2010510767A (ja) * 2005-11-30 2010-04-08 イマクシオ 抗原およびアジュバントの多量体複合体
JP2013507907A (ja) * 2009-10-16 2013-03-07 アイシス イノヴェイション リミテッド マイコバクテリアワクチン
JP2016501266A (ja) * 2012-12-11 2016-01-18 イマクシオＩｍａｘｉｏ 改善された特性を有する改変コイルドコイル型タンパク質

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999012036A1 (en) * 1997-09-04 1999-03-11 Stanford University Reversible immobilization of arginine-tagged moieties on a silicate surface
US20070104726A1 (en) * 2002-08-14 2007-05-10 Avidis Sa Multimeric complexes of antigens and adjuvants
EP2060586A1 (en) * 2007-11-14 2009-05-20 PharmaSurgics in Sweden AB New synthetic arginine substituted peptides and their use

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0795888A (ja) * 1993-03-18 1995-04-11 Merck & Co Inc 核酸製剤
JP2007528210A (ja) * 2003-08-12 2007-10-11 アヴィディス エスアー Ｃ４ｂｐコアタンパク質及び単量体抗原を含む生成物及びその使用
JP2010510767A (ja) * 2005-11-30 2010-04-08 イマクシオ 抗原およびアジュバントの多量体複合体
JP2013507907A (ja) * 2009-10-16 2013-03-07 アイシス イノヴェイション リミテッド マイコバクテリアワクチン
JP2016501266A (ja) * 2012-12-11 2016-01-18 イマクシオＩｍａｘｉｏ 改善された特性を有する改変コイルドコイル型タンパク質

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ARCHIVES OF VIROLOGY, vol. 151, JPN6018004154, 2006, pages 921 - 931, ISSN: 0003995927 *
NATURE, vol. 444, JPN6018004156, 2006, pages 1078 - 1082, ISSN: 0003995928 *

Also Published As

Publication number Publication date
CA2901888A1 (en) 2014-09-25
AU2014234363B2 (en) 2018-02-15
BR112015023738A2 (pt) 2017-11-21
CN105143251B (zh) 2021-05-11
BR112015023738B1 (pt) 2023-01-10
WO2014147087A1 (en) 2014-09-25
CN113307881A (zh) 2021-08-27
US20150098958A1 (en) 2015-04-09
EP2976357B1 (en) 2018-10-17
CA2901888C (en) 2023-06-20
US20160215032A1 (en) 2016-07-28
RU2662667C2 (ru) 2018-07-26
EP2976357A1 (en) 2016-01-27
MX2015013304A (es) 2015-12-15
KR20150131292A (ko) 2015-11-24
CN105143251A (zh) 2015-12-09
MX363149B (es) 2019-03-11
BR112015023738B8 (pt) 2023-02-14
AU2014234363A1 (en) 2015-09-03
US9963490B2 (en) 2018-05-08
US9243047B2 (en) 2016-01-26
KR102379951B1 (ko) 2022-03-31
RU2015140603A (ru) 2017-04-21

Similar Documents

Publication Publication Date Title
US9777045B2 (en) Immunogenic compositions and methods
Kim et al. Multiple heterologous M2 extracellular domains presented on virus-like particles confer broader and stronger M2 immunity than live influenza A virus infection
JP2016520534A (ja) インフルエンザ核タンパク質ワクチン
RU2677799C2 (ru) Модифицированные суперспиральные белки с улучшенными свойствами
Deng et al. Protein nanoparticle vaccine based on flagellin carrier fused to influenza conserved epitopes confers full protection against influenza A virus challenge
JP2016117757A (ja) 免疫応答を増強するワクチンベクターおよび方法
Verma et al. Norovirus (NoV) specific protective immune responses induced by recombinant P dimer vaccine are enhanced by the mucosal adjuvant FlaB
JP7686302B2 (ja) 融合遺伝子、組換え新型コロナウイルス高効率免疫ｄｎａワクチン、それらの構築方法及び使用
Fan et al. Incorporation of a bi-functional protein FimH enhances the immunoprotection of chitosan-pVP1 vaccine against coxsackievirus B3-induced myocarditis
JP5735121B2 (ja) インフルエンザウィルスの組換えヘマグルチニン蛋白質及びそれを含むワクチン
JP4382163B2 (ja) ターゲッティング分子を用いた免疫応答の増強
Zhao et al. Cross-protection against homo and heterologous influenza viruses via intranasal administration of an HA chimeric multiepitope nanoparticle vaccine
CN116514991A (zh) 一种β冠状病毒和流感嵌合抗原、其制备方法和应用
US11672852B2 (en) Universal mammalian influenza vaccine
CN115850398B (zh) 新型冠状病毒奥密克戎系列变异株的多肽组合物及其应用
WO2024152998A1 (zh) CpG佐剂在制备新型冠状病毒疫苗中的应用
JP2013545733A (ja) ヒト免疫不全ウィルス（ｈｉｖ）の組換えエンベロープ蛋白質及びそれを含むワクチン
KR102211077B1 (ko) 바이러스 유사 입자를 이용한 슈도-타입 광견병 백신
Lobaina et al. A nasal vaccine candidate based on S2 and N proteins from SARS-CoV-2 generates a broad antibody response systemically and in the lower respiratory tract
ES2719256T3 (es) Proteínas de tipo superhélice modificadas que presentan unas propiedades mejoradas
Wang et al. Peptide (rTa1-BP5) Enhances Protection Against Influenza Through Humoral and Cell-Mediated
Park Ochsner MUCOSAL DELIVERY OF INFLUENZA VACCINE ANTIGENS
Hagenaars et al. Head-to-head comparison of four nonadjuvanted inactivated cell culture-derived influenza vaccines
Chen et al. Influenza H7N9 Virus Hemagglutinin With T169A Mutation Possesses Enhanced Thermostability and Shows Improved Immune Protection Against Lethal H7N9 Virus Challenge in Chickens

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170307

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170307

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20180130

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180131

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180702

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180720

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181022

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20190315

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190617

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20190815

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191206